Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)Kinuko Hirose, Kanji Sugita, Hajime Okita et al.|Blood|2010Cited by 39
Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptorsXiaoliu Zhang, K Sugita, Takeshi Inukai et al.|Leukemia|2012Cited by 17
Specific induction of CD33 expression by E2A–HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factorKoshi Akahane, K Sugita, Takeshi Inukai et al.|Leukemia|2010Cited by 14
E2A-HLF Fusion Transcription Factor Mediating Aberrant Expression of LMO2 in B-Precursor ALL with t(17;19).Kinuko Hirose, Kanji Sugita, Takeshi Inukai et al.|Blood|2006Cited by 0
Induction of Death Receptors for TRAIL, a Cytotoxic Factor for GVL Effect, by Oncogenic Fusion E2A-HLF Derived from t(17;19)-Positive Acute Lymphoblastic Leukemia.Xiaochun Zhang, Kanji Sugita, Takeshi Inukai et al.|Blood|2007Cited by 0